Contact the Editorial Desk

Editorial correspondence

The most useful message this desk receives is a correction. A figure quoted loosely, a trial that has posted results since an entry was written, a regulatory status that has moved, or a peer-reviewed study on semaglutide, tirzepatide or retatrutide that belongs on the source list — each of those improves the record and each is read and weighed.

This desk has a standing interest in one category in particular. Withdrawal arms and off-treatment extensions are published less prominently than the trials they follow, and a pointer to one that is not represented here is the single most valuable thing a reader can send.

Notes that are easiest to act on name three things: the page, the exact passage in question, and the supporting source with a DOI or PubMed identifier where one exists. In that form a proposed change can be checked against its source before anything is rewritten.

Editorial mailbox: editors@brandmypeptides.com

Outside this desk's remit

So that no message waits for an answer that is never coming, several categories sit outside what a literature digest can do. This desk cannot advise on, endorse or comment on human use of any compound covered here; cannot name a quantity, schedule, route or preparation for any individual; cannot judge whether a trial finding applies to a particular situation; and cannot sell, source, formulate, label, recommend or help locate material from any supplier.

Questions about starting, continuing or stopping a prescription medicine are the clearest case of all. They are clinical decisions, they depend on facts about a person that no reference page has, and they belong with the prescriber who wrote the prescription rather than with a summary of trial literature.

Retatrutide is investigational and available legitimately only through a clinical trial, so questions about obtaining or administering it have no answer this desk can give.